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Gold(III) Complexes for Anti-tumour Applications: an Overview 
Benoît Bertrand,[a], [b]* Morwen R. M. Williams,[a] and Manfred Bochmann[a]*
Abstract: Gold(III) complexes have emerged as a versatile and 
effective class of metal-based anticancer agents. The development 
of various types of ligands capable of stabilizing the Au(III) cation 
and preventing its reduction under physiological conditions, such as 
chelating nitrogen-donors, dithiocarbamates and C^N cyclometalled 
ligands, has opened the way for the exploration of their potential 
intracellular targets and action mechanisms. At the same time, the 
bioconjugation of Au(III) complexes has emerged as a promising 
strategy for improving the selectivity of this class of compounds for 
cancer cells over healthy tissues, and recent developments have 
shown that combining gold complexes with molecular structures that 
are specifically recognized by the cell can exploit the cell’s own 
transport mechanisms to improve selective metal uptake. 
 
Introduction 
 
The discovery of the anticancer properties of cis-
diamminedichloroplatinum(II) (cisplatin) in the 1960s marked the 
start of the modern era in the discovery and use of metallodrugs.
[1]
 
However, among the thousands of platinum-based compounds 
tested for anticancer applications, only two of them, carboplatin and 
oxaliplatin, have reached worldwide approval.
[2]
 Those platinum-
based drugs are highly effective chemotherapeutic agents and they 
are widely used for the treatment of various types of cancer, in 
particular head and neck, testicular and ovarian cancers.
[3]
 However, 
despite their clinical success, platinum-based metallodrugs do not 
specifically target cancer cells but also affect other rapidly dividing 
cells, such as those found in bone marrow and the gastrointestinal 
tract. This causes severe side effects which limit the administrable 
dose to patients.
[4]
 Other drawbacks include acquired or intrinsic 
drug resistance as well as a limited spectrum of action.
[5]
 All of these 
factors have driven the interest towards the development of 
metallodrugs based on other transition metals.
[6]
  
The pharmacologic properties of gold have been known since 
the end of 19
th
 century, and gold compounds have been tested 
against different pathologies, even though they are currently only 
used for the treatment of rheumatoid arthritis.
[7]
 Auranofin, (2,3,4,6-
tetra-O-acetyl-1-(thio-κS)--D-glucopyranosato)(triethyl-
phosphine)gold(I), is an orally administrated anti-arthritis drug which 
has also been studied for its antiproliferative properties.
[8]
 Based on 
those results, different Au(I) complexes bearing phosphine,
[9]
 
NHC,
[10]
 alkynyl
[11]
 and thiolate
[12]
 ligands have been synthesized and 
tested as prospective anticancer drugs. Their mechanism of action 
has been investigated and Au(I) complexes are thought to trigger 
apoptosis via inhibition of selenium- and sulfur-containing enzymes 
such as thioredoxin reductase (TrxR), glutathione peroxidase, 
cysteine protease or glutathione-S-transferase.
[13]
 Au(III) has a d
8
 
electronic configuration and is thus isoelectronic with Pt(II) and, like 
platinum, forms four-coordinated square-planar complexes, and it 
was therefore initially assumed that Au(III) would provide a good 
alternative for Pt(II) and show a similar mode of action as anti-cancer 
treatment. However, due to the reducing intracellular environment 
(for example, the reduction potential of glutathione is about -0.36 
V
[14a]
) the tendency of Au(III) centre to be reduced to Au(I) or to 
Au(0) particles makes the choice of ligands particularly relevant.
[14b]
 
This review provides an overview and evaluation of the different 
classes of Au(III) complexes used as prospective anticancer drugs. 
The area of gold complexes with anti-cancer activity has developed 
fast in recent years and the evolution of the field has been regularly 
reviewed.
[6,10,13] 
We focus here on the most recent evidence of their 
possible modes of action, with emphasis on current strategies aimed 
at increasing the selectivity of antiproliferative gold complexes 
towards their cellular targets.
 
 
1. Gold(III) complexes with chelating N-donor ligands 
Some of the first gold(III) complexes examined for anticancer 
applications were pyridine-based complexes [AuCl3(Hpm)] and 
[AuCl2(pm)] (Hpm = 2-pyridylmethanol). They were tested in vitro 
against a panel of cancer cell lines and demonstrated comparable 
activities to cisplatin and NaAuCl4. The compounds were shown to 
interact closely with proteins such as albumin and transferrin but 
only weakly and reversibly with DNA.
[15]
 While this shows that 
gold(III) compounds have potential, the facile substitution of the 
chloro ligands by water at pH above 2 rendered them too unstable in 
a physiological environment for medicinal purposes.
[15]
 However, 
polydentate N-donor ligands successfully stabilize gold(III), such as 
ethylenediamine (en) (1), phenanthroline (phen) (2), 
diethylenetriamine (dien) (3), terpyridine (terpy) (4), macrocyclic 
ligands 1,4,8,11-tetraazacyclotetradecane (cyclam) (5) or 
aminoquinoline derivatives (6).
[16,17]
 Some of these complexes are 
depicted in Figure 1. The stability of some compounds was 
measured by cyclic voltammetry and UV-visible spectroscopy in the 
presence of reducing agents such as GSH. As mentioned earlier, the 
reduction potential of the complexes is strongly influenced by the 
ligands, and passing from phen to cyclam leads to changes in the 
reduction potential of the corresponding complexes ranging from 
+0.80 to -0.20 V vs normal hydrogen electrode. 
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Figure 1: Examples of Au(III) complexes with chelating N-donor ligands investigated for anticancer applications. 
 
However, although polyamine complexes were particularly stable, 
with complex 8 presenting the highest stability toward reduction, 
their cytotoxicity in vitro against ovarian cancer cells (A2780) 
appeared rather low.
[16]
 The most toxic compounds against the 
ovarian cancer cell lines A2780 appeared to be the least stable ones 
(2 and 4). Their activities were close to those of the respective 
ligands phen and terpy, which suggests that the toxicity of 2 and 4 
may arise from the reduction of Au(III) and the subsequent release 
of the phen and terpy ligands.
[16]
 The mechanism of action of those 
Au(III) complexes have been carefully investigated, starting with the 
potential interaction with DNA due to the electronic similarity with 
Pt(II). Although such interactions were shown to be possible, they 
are weak and reversible, thus ruling out DNA as primary target of 
that class of complexes.
[18]
 However, it is possible to increase the 
interaction of Au(III) complexes with DNA by modifying the ligands. 
Indeed, complex 6, with an aminoquinoline-based ligand, has been 
demonstrated to interact with DNA via an intercalation 
mechanism.
[17]
  
Complex 2 is a particularly good inhibitor of the water and 
glycerol channel aquaporins (AQPs).
[19]
 Using homology models, a 
methionine residue (presenting a thioether functional group) inside 
the AQP7 channel and a cysteine residue (presenting a thiol 
functional group) have been identified as the possible interaction 
points of 2 with AQP7 (Figure 2) and AQP3, respectively.
[20] 
Recently, it has been demonstrated that the coordination of the 
cysteine residue to Au(III) complexes induces a conformational 
change of the protein, leading to the shrinkage of the channel and so 
is mostly responsible for its inhibition.
[21]
 A more detailed theoretical 
study of the interaction of this class of Au(III) complexes with AQP3 
suggests that this interaction occurs after the replacement of a 
chloride ligand by a hydroxide. The thus generated 
[(N^N)Au(OH)Cl]
+
 could form a non-covalent adduct with the outer 
part of AQP3, followed by the coordination of the deprotonated 
cysteine residue to the [(N^N)Au(OH)]
2+
 fragment. This complex is 
further stabilized by π-stacking interactions from the phenyl ring of a 
phenylalanine residue with the aromatic rings of the (N^N) ligand.
[22]
  
 
Figure 2: Molecular docking of complex 2 (green) inside the channel 
of human AQP7 (grey) (reproduced from ref. 20a with permission 
from the publisher). 
 
The zinc-finger enzyme poly(ADP)ribose polymerase 1 
(PARP-1) has been identified as another possible target of complex 
2. According to mass spectrometry measurements inhibition occurs 
via displacement of zinc upon loss of all ligands coordinated to 
gold.
[23]
 When reacted with model peptides mimicking (Cys2His2) and 
(Cys2HisCys) zinc-finger domains, 2 has been shown to displace 
Zn
2+
 with the same efficacy in both cases, leading to the formation of 
a “gold-finger” while maintaining the +III gold oxidation state. The 
change from the tetrahedral environment of Zn(II) to the square-
planar geometry of Au(III) led to important conformational 
modifications (see Figure 3) which are potentially responsible for the 
inhibition of the enzyme by 2.
[24]
 Interestingly, the reaction of the 
(N^N^N)AuCl pincer complex 4 with a (Cys4) zinc-finger domain led 
to fast reduction to Au(I), together with formation of a Cys-Au(I)-Cys 
moiety and a disulphide bridge.
[25] 
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Figure 3: Overlay of the calculated structures of the (Cys2His2) zinc-
finger domains in the presence of Zn(II) (brown) and Au(III) (blue) 
cations (reproduced from ref. 24 with permission from the publisher). 
 
The dimeric oxo-bridged complex 7 is active in the low 
micromolar range against cisplatin-sensitive (A2780/S) and cisplatin-
resistant (A2780/R) ovarian cancer cell lines. Using UV-visible 
spectroscopy, complex 7 has been shown to be quite stable in 
aqueous solution, although some aquation leading to the formation 
of the monomeric bis-hydroxo complex could occur. However, 7 is 
easily reduced by natural reductants like ascorbic acid or 
glutathione.
[26]
 Against a panel of 36 cancer cell lines 7 had high 
activity with a good selectivity score. Using COMPARE analysis, the 
toxicity pattern of 7 was correlated with one of several histone 
deacetylase (HDAC) inhibitors.
[27]
 Proteomic studies carried out on 
A2780 cells using 2D-differential gel electrophoresis (2D-DIGE) 
showed that upon treatment with 7 only a small fraction of the entire 
proteome presented a modified expression. Most of these proteins 
were involved in redox homeostasis, pointing to oxidative stress as 
the potential primary mechanism of action for 7. Moreover, the close 
correlation of these results with those obtained with auranofin 
suggests that 7 might be reduced to a gold(I) species in the 
intracellular milieu.
[28]
 This is in good agreement with data obtained 
by spectrophotometric and mass spectrometry techniques with 
different model proteins like human serum albumin (hSA), 
cytochrome c (cyt c) and ubiquitin (Ubq). In all cases, the interaction 
was found to occur via redox processes triggering the destruction of 
the dimeric architecture.
[26]
  
Complexes based on the 2,6-bis(benzimidazol-2-yl)pyridine 
(HN^N^NH) ligand (8, Figure 1), although perfectly stable in an 
aqueous medium, were quantitatively and quickly reduced by GSH 
with release of the HN^N^NH ligand and formation of the 
corresponding (GS)Au(I)-(NHC) complexes. The free HN^N^NH 
ligand shows strong fluorescence which is quenched on coordination 
to a gold(III) cation, so that ligand release can be used to monitor 
gold uptake into cells. Using fluorescence microscopy, the authors 
could indeed observe the characteristic blue fluorescence of free 
HN^N^NH after 10 min of incubation of Hela cells with 8, consistent 
with the uptake of 8 into the cells and its reduction to Au(I). The 
compound with the highest anticancer activity was the one bearing 
the longest alkyl chain (n = 15), with a cytotoxic activity in the low 
micromolar range associated with the highest intracellular gold 
uptake. Complex 8 reduced the size of Hela xenografts in mice in 
vivo, making these compounds suitable as dual agents for 
anticancer and thiol sensing applications.
[29] 
 
2. Gold(III) complexes with porphyrin ligands 
 Gold(III) porphyrin complexes are a class of compounds 
characterized by very high redox stability (Ep = -1.00 and -1.48 V vs 
Cp2Fe
0/+I
) in acetonitrile, but also by their stability in the presence of 
natural reductants such as glutathione. The tetraphenylporphyrin 
complex 9 (Figure 4) was tested against a panel of human cancer 
cell lines including drug-resistant variants, such as the multi-drug 
resistant human oral carcinoma (KB-V1) and cisplatin-resistant 
human nasopharyngeal carcinoma (CNE1). 9 showed sub-
micromolar activity across the board, suggesting a different 
mechanism of action from cisplatin.
[30]
 In vivo studies on mice 
showed that 9 reduced nasopharyngeal carcinoma tumour growth 
without body weight loss or liver injuries. The mechanism of action of 
9 involves reduction of mitochondrial membrane potential, which 
triggers the release of cytochrome c and apoptosis-activating factor 
leading to apoptosis.
[31]
 The heat-shock protein 60 (Hsp60), an 
important chaperone involved in the transport and folding of 
mitochondrial proteins, has been identified as a major molecular 
target of 9. Replacing the Au(III) cation by a Pt(II) one or using a 
cyclometalated ligand led to a complete loss of the inhibitory activity, 
highlighting its dependence of the activity on both the Au(III) ion and 
the porphyrin ligand.
[32]
  
The PEGylated complexes 10a and 10b (Figure 4) have 
been shown to self-assemble in aqueous solution into core-shell 
micelles with diameters in the range of hundreds of nanometers. 
These structures accumulate faster and more selectively in the 
cancer cells than non-PEGylated analogues. This may potentially be 
due to the “enhanced permeability and retention” (EPR) effect (which 
refers to the higher permeability of cancer cells membranes as the 
result of their excessively fast development), although that effect is 
nowadays more and more debated.
[33]
 In acidic conditions, which 
prevail in the intracellular space between cancer cells in solid 
tumours, the ester function in complex 10a can be cleaved within 
few hours, causing the release of the free Au(III) complex, while the 
amide in 10b is much more stable. Thus both 10a- and 10b-based 
micelles can enter cancer cells easily, but the release of the active 
monomeric Au-porphyrin fragment is faster and more efficient for the 
ester 10a. This causes 10a to be much more cytotoxic than 10b. 
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Moreover, the self-assembly capacity of 10a has been used to 
encapsulate and deliver the clinically-used anticancer drug 
doxorubicin into cancer cells, including into doxorubicin-resistant 
cells.
[34] 
 
Figure 4: Structures of the porphyrin-based gold complexes 
investigated for anticancer applications. 
 
3. Gold(III) complexes with dithiocarbamate ligands 
Gold(III) dithiocarbamate (DTC) complexes are 
characterized by two Au-S bounds which stabilize the +III oxidation 
state, as demonstrated by cyclic voltammetry: 5 mV ≤ Ep(AuDTC) ≤ 
125 mV (Ep = peak potential) compared to Ep = 1.29 V vs SCE for 
KAuX4 (X = Cl, Br) (Figure 5).
 
Complexes 11a/b (Figure 4) have 
been tested in vitro against a series of human cancer cell lines 
including leukemia, cervical adenocarcinoma, colon adenocarcinoma 
and malignant melanoma. They demonstrated cytotoxicities up to 
nanomolar levels against leukemia (HL60), lymphoma (Daudi) and 
melanoma (MeWo) cells. This high antiproliferative activity was 
accompanied by a lack of cross resistance with cisplatin, suggesting 
a different mode of action.
[35]
 In prostate cancer (PC3) cells in vitro, 
11a has been demonstrated to trigger the overexpression of reactive 
oxygen species (ROS), to inhibit TrxR, and to induce apoptosis via 
mitochondrial membrane depolarization and activation of caspase-
9.
[36]
 Proteasome, an important actor of the protein degradation 
machinery in cells, has also been identified as a primary target of 
11b both in vitro and in vivo.
[37]
  
In order to improve the selectivity of gold dithiocarbamate 
complexes, one strategy investigated involved the coupling of 
dipeptides to the Au(DTC)X2 scaffold, to facilitate the internalization 
of the compounds via peptide transporters. To this end, dipeptides 
were introduced on the DTC ligand to give compounds of type 12 
(Figure 5). Complex 12 showed strong antiproliferative activity 
against a panel of five cancer cell lines expressing the peptide 
transporters PEPT1 and PEPT2.
[38]
 Cationic [Au(DTC)2]
+
 complexes, 
e.g. 13, have also been synthesized and tested. They exert a 
cytotoxicity very similar to that of mono-DTC analogues of type 11. A 
mass spectrometry study of the interaction of 13 and its mono-DTC 
analogue with sulfur-containing species revealed that in both cases 
the cationic [Au(DTC)2]
+
 was bound to cysteine or GSH. This 
suggests that in all cases the [Au(DTC)2]
+
 cation might be 
responsible for these interactions.
[39] 
Gold complexes containing cyclometalated 2-
phenylpyridine or 2,2′-bipyridyl as well as DTC ligands (Figure 5, 14 
and 15) provide other types of coordinatively stable complexes.
[40,41]
 
Complex 14 effectively inhibits different deubiquitinases (DUBs). 
DUBs are proteases responsible for the cleavage of the bond 
between ubiquitin (Ub) and proteins. Ubiquitination of proteins 
serves as a “labelling” of proteins for their degradation by the 
proteasome. Thus, DUBs are involved in different cellular processes 
including cell cycle, chromatin remodelling or signalling pathways 
modified in cancer cells such as the ones involving p53 or 
transforming growth factor-β (TGF-β).
[42]
 Beyond the deubiquitinase 
inhibition activity, 14 triggers apoptosis and has anti-angiogenesis 
properties in breast cancer cells MCF-7.
[40]
 Replacing a C^N 
cyclometalated ligand by N^N = 2,2′-bipyridyl leads to 15, with a 
cytotoxicity in the sub-micromolar range. The anticancer activity of 
15 is p53-independent and is apparently based on the mitochondrial 
apoptotic pathway.
[41]
 This mechanism seems to be a common 
feature of the Au(DTC) complexes.  
 
 
Figure 5: Examples of Au(III) dithiocarbamate complexes 
investigated for anticancer applications. 
 
4. Gold(III) complexes with cyclometalated ligands 
(C^N)Au(III) complexes. 
Cyclometalated ligands are chelates with a covalent M-C and 
a coordinative M-E bond (E = N, O, P, S or Se) and are particularly 
successful in stabilizing Au(III) against reduction. C^N chelates are 
most widely used, alongside C^N^N, N^C^N and C^N^C pincer 
ligands.
[43]
 The high stability of the cyclometalated Au(III) complexes 
has enabled the study of reaction intermediates,
[44]
 fundamental 
organometallic reactions,
[45]
 and development of photoemissive 
complexes.
[46]
   
The first report of the use of cyclometalated Au(III) complexes 
as potential anticancer agents described complexes based on the 
(C^N) ligand 2-(N,N-dimethylamino)methylphenyl (complexes 16 
and 17, Figure 6).
[47,48]
 Those complexes appeared more toxic than 
cisplatin on a panel of human cancer cells in vitro. The acetato and 
malonato derivatives (16c and 17b respectively) had the most 
interesting antiproliferative activity and were able to overcome 
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cross-resistance with cisplatin when tested on ovarian cancer cells 
sensitive and resistant to cisplatin (A2780 and A2780-R 
respectively).
[48] 
When tested in vivo on mice bearing tumour 
xenografs, these complexes had an anti-tumour activity comparable 
to cisplatin.
[47,48]
 These complexes have been demonstrated to be 
potent inhibitors of the cysteine protease cathepsin B.
[49]
 Replacing 
the -NMe2 moiety in complexes of type 16 and 17 by pyridyl (as in 
18 and 19) and varying the spacer between the rings from CH2 to 
CR2, C=O, O, S, S=O, NH, or NR (where R = alkyl, aryl or 
functional group) provides a large palette of derivatives of the C^N 
structural motif. The thiosalicylato compound 19b has been 
identified as a particularly potent inhibitor of cathepsin B and K, with 
in vitro antiproliferative activity in the low micromolar range against 
a panel of human cancer cell lines.
[50]
 
The phosphine containing complex 18c and its dichloro 
analogue 18a were found to inhibit the zinc-finger enzyme PARP-1 
at nanomolar levels.
[51]
 Further computational and mass 
spectrometry investigations have highlighted the ability of 18a to 
discriminate different zinc-finger domains and to have a higher 
affinity for the (CysCysHisCys) zinc-finger domain found in PARP-1, 
over the (CysCysHisHis) zinc-finger domain. Whereas the (N^N) 
complex 2 reacts with zinc-finger domains with the loss of the N^N 
ligand, the cyclometalated C^N complex 18a maintains the 
(C^N)Au(III) motif upon reaction with the zinc-finger domain (Figure 
7).
[52]
 This may open the way to the development of highly selective 
PARP-1 inhibitors.  
 
 
Figure 6: Examples of cyclometalated (C^N)Au(III) complexes. 
 
Uptake/efflux studies on precision-cut kidney slices using 
complex 18c and cisplatin have demonstrated that both active and 
passive mechanisms are involved and that in the case of 18c the 
efflux might occur predominantly through active processes. The 
major involvement of the organic cation transporters (OCTs) and the 
multidrug and toxin extrusion protein (MATE) transporters into the 
uptake mechanism of 18c could be ruled out.
[53]
  
Figure 7: Calculated structure of the most stable isomer due to the 
reaction between the (Cys2HisCys) zinc-finger domain of PARP-1 
and complex 18a (reproduced from ref. 52 with permission from the 
publisher). 
 
The more rigid cyclometalated C^N ligand scaffold based on 2-
phenylpyridine has also been explored to make anticancer 
organogold complexes with various ancillary ligands, including 
chloride, carboxylates, cyclobutanedicarboxylate, sulfur-containing 
ligands and phenyl derivatives (complexes 20 and 21, Figure 7). 
These complexes demonstrated antiproliferative properties similar to 
cisplatin on human leukemia (MOLT-4) and mouse tumour (C2C12) 
cell lines, with the cyclobutanedicarboxylato complex being the most 
promising compound of that series.
[54]
 Coupling the lipophilic nature 
of the (C^N)Au fragment to the hydrophilic character of the 
biguanide ligand as in 22 led to a compound displaying a high in 
vitro antiproliferative effect on Hela cells associated with low toxicity 
towards normal lung fibroblasts. The compound reacts with GSH to 
form aggregates without reduction of the Au(III) center. Mechanistic 
studies on 22 pointed to endoplasmic reticulum (ER) swelling 
triggered by ER-stress induction, as evidenced by the up-regulation 
of ER-stress markers such as GRP78/Bip, CHOP and HSP70. 22 
also displayed anti-angiogenic effects at sub-cytotoxic 
concentrations.
[55]
 TrxR has also been identified as a possible 
intracellular target of analogues of complex 23 (Figure 6). Moreover, 
23 was shown to increase the amount of intracellular ROS in Hela 
cells.
[56]
 
Imminophosphorane have been used as cyclometalated 
(C^N) ligands to generate analogues of 24. The chloro ligands can 
easily be substituted, e.g. by as dithiocarbamates or phosphines. 
These compounds appeared particularly efficient against acute 
lymphoblastic leukemia cells (Jurkat). They are potent TrxR 
inhibitors and trigger apoptosis via a mitochondria-related pathway 
involving ROS production and mitochondrial membrane 
depolarization.
[57]
 The hydrophobic/hydrophilic balance of these 
systems can easily be tuned by using a more water-soluble 
phosphine such as the 1,3,5-triaza-7-phosphaadamantane (PTA).
[58] 
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(C^N^N)Au(III) complexes 
Compound 25 (Figure 8) bearing a 6-(1,1-dimethylbenzyl)-
2,2′-bipyridine ligand was shown to be stable toward reduction even 
in the presence of reductants like sodium ascorbate, while the 
(N^N)Au(III) (based on bipy or phen ligands, figure 1) were easily 
reduced under the same conditions.
[16,59]
 25 has been shown to be 
highly cytotoxic against A2780 ovarian cancer cells despite a weak 
interaction with DNA. Its mechanism of action is likely due to 
inhibition of enzymes via the direct interaction of the (C^N^N)Au(III) 
fragment with different proteins and enzymes, without reduction of 
the Au(III) cation. Such interactions have been described with bovin 
serum albumin (BSA),
[60] 
cytochrome c, lysozyme
[61]
 and the enzyme 
thioredoxin reductase.
[62]
 Using mass spectrometry techniques, the 
preferred interaction of 25 with selenocysteines over histidine, 
cysteine, methionine and glutamate has been highlighted, along with 
the weak interaction with 9-ethylguanine and guanine-based 
nucleotides. This correlates with TrxR being a major target of 25.
[63]
 
Several lines of evidence point towards the involvement of the 
copper trafficking system into the uptake mechanism of gold 
complexes. Indeed, 25 has been shown to form stable adducts with 
the copper chaperone Atox-1 and to compete with the binding of 
copper(I).
[64] 
25 has also been identified as an inhibitor of the 
transmembrane transporter Na
+
/K
+
-ATPase
[65]
 and the 20S 
proteasome sub-unit.
[66]
 In order to observe the effects triggered by 
25 on the expression of the proteins of a whole cell, proteomic 
analyses have been performed using 2D-DIGE methodologies. 
When comparing samples of A2780 ovarian cancer cells treated with 
25 to samples of the untreated cells, the expressions of only few 
proteins were found to be modified (up- or down-regulated). These 
proteins could be identified by MALDI-TOF mass spectrometry 
techniques.
[67]
 Most of the over-expressed proteins were shown to 
belong to the ‘stress response and chaperones’ functional class. The 
down-regulated proteins appeared to be involved in the glucose 
metabolism pathway and more generally speaking in energy 
production. Treatment with 25 therefore seems to trigger cellular 
stress via the down-regulation of the glucose metabolism pathway. 
Complex 26 (Figure 8), the xylidine analogue of 25, showed 
improved antiproliferative activity compared to 25 against A2780 and 
MCF-7 cells.
[68]
 The COMPARE analysis of the results from a panel 
of 36 cell lines suggested the inhibition of mammalian target of 
rampamycin (mTOR), proteasome and DNA synthesis as potential 
mechanism of action.
[27] 
TrxR has been identified as another 
potential target of 26 through the interaction with the cysteine and 
selenocysteine residues.
[69]
  
The oxo-bridged compound 27 (Figure 8) is reversibly 
hydrolysed to give two equivalents of 25. The latter has been 
identified as the binding fragments with various proteins (lysozyme 
and cytochrome c).
[70] 
In the same way, hydrolysis of 27 to 25 leads 
to the stabilization of the non-canonical G-quadruplex structure of 
DNA.
[71] 
 
Figure 8: Cyclometalated (C^N^N)Au(III) hydroxide and amide 
complexes. 
 
(C^N^C)Au(III) complexes 
Pincer complexes (C^N^C)Au(III)X (X = halide, N-, C- or 
P-donor) based on the 2,6-diphenylpyridine ligand, such as 28 
(Figure 9), have shown promising anticancer properties in vitro.
[72]
 
This ligand platform is very stable and synthetically versatile and has 
opened the way to a large series of derivatives of type 29 with 
different ancillary ligands, including 1-methylimidazole, pyridine, 
triphenylphosphine, PTA and thio-β-D-glucose tetraacetate.
[72,73]
 
Modifications of the pincer ligand has also been explored by benzo-
annelation of the phenyl rings (as in 2,6-dinaphthylpyridine) or by 
introducing another aromatic substituent on the pyridine (2,4,6-
triphenylpyridine), although these modifications do not seem to 
significantly modify the antiproliferative properties. On the other hand, 
changing the ancillary ligands X seems to have a major impact on 
the biological properties of the complexes. The N-methylimidazole in 
29 (R =H) enhances the ability of the complex to intercalate with 
double-stranded DNA and to interact with G-quadruplex DNA, 
making DNA a potential target for that compound, whereas the 
phosphine-containing analogues interact only weakly with DNA. In 
the same way 29 (L = N-methylimidazole) blocks the cell cycle in the 
S-phase i.e. when the DNA has been replicated and so when the 
amount of DNA is the highest, while the binuclear complex 30 was 
unable to do so even after 48 h of incubation.
[72] (C^N^C)Au 
complexes of bridging 1,3-bis(diphenylphosphino)propane (30, 
Figure 9) proved particularly effective in vitro against human 
hepatocellular carcinoma and human cervical epithelial carcinoma 
cells.
[72,74]
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Figure 9: Examples of cyclometalated (C^N^C)Au(III) complexes investigated for anticancer applications. 
 
However, the cytotoxicity of these complexes appeared to be 
very close to that of the free diphosphine ligands themselves, which 
suggests that the complexes may simply act as carriers of the 
cytotoxic ligands. Based on that finding the more stable NHC 
analogues have also been tested and have shown much lower 
toxicity. Ligand lability therefore seems important for antiproliferative 
activity.
[72,74]
 When tested in vivo on nude mice bearing 
hepatocellular carcinoma xenografts, 30 could reduce tumour growth 
more efficiently than cisplatin or doxorubicin, while no side-effects 
were observed. 30 has been shown to very effectively inhibit TrxR 
and induce ER stress leading to apoptosis.
[74]
  
The [(C^N^C)Au(NHC)]
+
 complex 31 inhibits 
topoisomerase 1 (Topo1), an enzyme responsible for the unwinding 
of chromosomal DNA, by stabilizing the cleavable topo1/DNA 
complex with higher efficacy than the known Topo1 poison 
comptothecin. This stabilization of the cleavable topo1/DNA complex 
prevents the relegation after unwinding, leading to DNA strand 
breaks.
[75]
 Complex 31 proved to be highly toxic against various 
human cancer cell lines in vitro and in vivo in nude mice bearing 
hepatocellular carcinoma xenografts (IC50 ~ 0.2 to 1.2 µM).
[75]
  
To gain a broader picture of the mechanism of action of 
this class of [(C^N^C)Au(NHC)]
+
 complexes, 32 has been developed. 
This compound presents two complementary functional groups: a 
photolabile diazirine unit, and an alkynyl grafting function. When 
irradiated with UV light (λ = 365 nm), the diazirine releases N2 and 
covalently binds with its closest neighbour, which will be the 
biomolecule with which it interacts. Then the alkynyl group was used 
to graft an azido-biotin fragment by the usual click-reaction, which 
enables the detection of 32/protein conjugates with streptavidin-
peroxidase.
[76]
 Only six proteins were observed to be bound to 32; 
these were identified as heat shock protein 60 (HSP60), vimentin 
(VIM), nucleoside diphosphate kinase A (NDKA), nucleophosmin 
(NPM), nuclease-sensitive element binding protein (Y box binding 
protein, YB-1), and peroxiredoxin 1 (PRDX1) which are all reported 
possible anti-cancer targets. When the same experiment was carried 
out with Hela, NCI-H460 and HCT116 the same six proteins were 
identified. Proteomic analysis of Hela cells highlighted the 
modulation of the eukaryotic initiation factor 2 (eIF2) signalling 
pathway involved in the synthesis of proteins upon treatment with 32. 
Proteomic data are in good agreement with the identified targets 
since VIM, NPM and YB-1, three of the identified protein targets, are 
involved in eIF2 signalling pathway modulation.
[76]
 Interestingly, 
proteins involved in protein synthesis have been similarly found to be 
down-regulated upon treatment with the (C^N^N)Au(III) complex 25 
(Figure 8), pointing toward a general mode of action for 
cyclometalated Au(III) complexes.
[67] 
 
Replacing the central pyridine ring by a pyrazine 
enhanced the photoemissive properties of the corresponding 
(C^N^C)Au(III) complexes and increases the tendency toward π-
stacking and H-bonding.
[77]
 This scaffold has been used to develop a 
library of complexes with various ancillary ligands including NHCs 
and the anti-cancer drug thioguanine (complexes 33 and 34).
[78]
  The 
cytotoxic profile of complex 34 was very similar to that of the free 
thioguanine, suggesting that, as was the case with 30, the gold 
complex may act merely as the carrier of the antiproliferative agent.  
The benzimidazol-2-ylidene complex 33 was found to be 
highly active in vitro against a panel of human cancer cell lines (IC50 
between 0.3 and 8 µM). Interestingly, the caffeine-based analogue 
of 33 appeared 10 times less toxic on all studied cells lines. These 
differences in activity could be rationalized by reduced intracellular 
gold uptake, as measured by inductively coupled plasma-mass 
spectrometry (ICP-MS) techniques, which may suggests that uptake 
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might occur by passive diffusion across the cell membrane which is 
impeded by carbene ligands with very polar structural elements. The 
polarity and degree of functionalisation of the NHC ligands are 
therefore important for the anticancer properties.
[78]
  
Compound 33 proved to be active also against cisplatin-
resistant cell lines, and it could be shown that 33 is resistant to 
reduction or substitution by GSH over a period of several days. 
There are several potential modes of action for such a complex; for 
example, 33 is able to stabilize selectively both the G-quadruplex 
and the i-motif structures of DNA, compared to the canonical double 
helix DNA structure, and it disrupts the protein-protein interaction 
between MDM2 and p53.
[78]
 Indeed, using biochemical and 
molecular docking techniques and saturation transfer difference 
NMR spectroscopy, 33 has been shown to interact with MDM2 on 
the p53 interaction site as depicted in Figure 10. 
 
Figure 10: Representation of 33 (gray) docked in MDM2 (green) 
(reproduced from ref. 78 with permission from the publisher). 
 
The concept of multinuclearity, i.e. the incorporation of 
several metal centres into a single molecule, has shown some 
promising results in terms of increasing the cytotoxicity of the 
compounds
[79] 
or enabling their cellular localization (i.e. synthesis of 
theranostics) by incorporating a luminescent or radioactive metal.
[80]
 
Using an NHC ligand bearing a pentafluorophenol ester moiety has 
enabled a post-metalation introduction of a second metal complex 
with high yield and selectivity.
[81]
 A similar strategy has been used to 
synthesize the series of homobimetallic Au(III)/Au(I) complexes 35 
with different alkyl spacers between the two gold cations.
[82]
 The 
complex with the longest linker showed activity only against the two 
breast cancer cell lines (MCF-7 and MDA-MB-231) but also showed 
a reduced activity against healthy fibroblasts. As for the 
monometallic complex 33 the differences in activity between the cell 
lines seem to be linked to differences in intracellular gold uptake. 
Compared to 33, the presence of the NHC-AuCl moiety in 35 did not 
decrease the interaction of this compound with the G-quadruplex 
structure of DNA, which suggests that the Au(I) fragment does not 
prevent the recognition of the (C^N^C)Au(III) moiety by cellular 
targets.
[82]
 On the contrary, although NHC-AuCl are not reported to 
stabilize the G-quadruplex structure of DNA,
[83]
 the introduction of 
the Au(I) fragment increased the interaction of 35 with the G-
quadruplex structure of DNA compared to the Au(III) complex with 
the pending amino linker.
[82]
 
 
 
In order to enhance the selectivity of metal-based drugs 
toward cancer cells, a particular promising strategy appears to be 
the conjugation of the metal complex with a vector molecule which 
can be recognized by receptors and transporters that are over-
expressed by cancer cells. This vector can be of different types: 
peptides, sugars, vitamins or aptamers.
[84]
 However, the 
bioconjugation can be difficult to carry out and may lead to overall 
poor synthetic yields. This can limit the number of permutations that 
can be explored in terms of metal-based compounds, spacers and 
vectors. Thus, it is important to develop simple, high yielding and 
versatile bioconjugation methods.  Reacting nucleophiles with an 
electrophilic isocyanide complex [(C^N^C)Au(C≡N-R)]
+
 leads to the 
formation of the corresponding acyclic carbene complexes of type 36, 
as shown in Figure 11. The reaction has been tested with success 
with amines and amino esters to generate a series of complexes 
36.
[85]
 The compounds were tested against a panel of cancer cells 
and showed higher activity than cisplatin against A549, MCF-7 and 
MDA-MB-231. However, these acyclic carbene complexes proved 
more sensitive to reduction by GSH than the related complex 33 
bearing a cyclic carbene ligand. Since 36 did not induce 
overproduction of ROS, interference with the mitochondrial redox 
activity was ruled out as potential mechanism. 
Attaching a biotin fragment to the [(C^N^C)Au(NHC)]
+
 
backbone (complex 37, Figure 11), enabled its binding to avidin. The 
natural photoluminescence of the 38/avidin conjugate was enhanced 
by a factor of 45 in the presence of aggregated bovine serum 
albumin (BSA) among other proteins, while the presence of single 
stranded DNA among other DNA structures increased the 
luminescence intensity 30-fold, making it a selective detector for 
those biomolecules.
[86]
 Both 37 and the 37/avidin conjugate were 
more active than cisplatin against Hela, HepG2 and MDA-MB-231 
cells. The 37/avidin conjugate was shown to trigger apoptosis 
without inducing generation of ROS.
[86] 
Following the methodology developed for the synthesis of 
the homobimetallic complexes 35, the conjugation of biotin and 17α-
ethynylestradiol via different alkyl spacers has been achieved in high 
yields leading to complexes 38 and 39, respectively.
[82]
 Incubation of 
MCF-7 cells, expressing both biotin receptors (BR) and estrogen 
receptors (ER), with 38 and 39 led to a higher intracellular gold 
uptake compared to the non-conjugated complex 33. Moreover, the 
amount of intracellular gold was reduced in cells that did not express 
the biotin and estrogen receptors.  
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Figure 11: Examples of cyclometalated (C^N^C)Au(III) complexes conjugated to biomolecules. 
 
This suggests that the two biomolecules could selectively 
deliver the [(C^N^C)Au(NHC)]
+
 fragment to cancer cells provided 
these express the corresponding receptors. However, in spite of the 
increased metal uptake, the cytotoxic properties of 38 and 39 were 
reduced compared to the non-conjugated complex 33. When tested 
against one of the potential intracellular targets of the 33, DNA G-
quadruplex structures, compounds 38 and 39 showed no DNA 
interaction. The results indicate that while vectors covalently bound 
to a [(C^N^C)Au(NHC)]
+
 backbone can increase the uptake of 
antiproliferative agents, they can also disturb the ability of the metal-
based pharmacophore to interact with its target, resulting in overall 
reduced activity.
[80]
 Thus linking the vector to the [(C^N^C)Au(NHC)]
+
 
backbone via a “self-immolative” spacer, so that the gold fragment 
can be liberated from the vector after entering the cell, may open the 
way to highly effective and selective gold-based anticancer therapy. 
 
Conclusion 
 
 Although gold in the oxidation state +III in a physiological 
medium is often easily reduced to gold(I) or gold nanoparticles, the 
development of chelating ligands with nitrogen donors, 
cyclometalated structures and dithiocarbamates has opened the way 
to enable Au(III) complexes to be used for chemotherapeutic 
purposes. The mechanisms by which these compounds are able to 
exert antiproliferative effects are slowly beginning to emerge. 
Different trends have been highlighted, although details remain very 
sketchy. Improving the selectivity of the compounds for cancer cells 
over healthy tissue in order to limit the side effects remains a major 
challenge, although some promising results have been obtained. 
More sophisticated synthetic approaches are required to fully utilise 
the potential of Au(III) complexes for the development of new 
generations of anticancer drugs.    
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